Skip to main content

TScan Therapeutics, Inc.

TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001783328

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding TScan Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of TCRX: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders027+27
Shares010.1M+10.1M
Value$0$83.5M+$83.5M

New holders (27)

Institutions that held TScan Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to TCRX in Q3 2021
InstitutionSharesValue% of portfolio
BlackRock Inc.1,500,577$12.5M0.00%
Baker Bros. Advisors LP1,425,000$11.9M0.05%
HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse)1,282,976$10.7M0.14%
Ra Capital Management, L.P.1,255,317$10.5M0.15%
Deer IX & Co. Ltd.1,245,505$9.35M0.96%
Alphabet Inc.1,077,080$8.98M0.21%
DC Funds, LP630,000$5.25M20.63%
Adage Capital Partners GP, L.L.C.496,583$4.14M0.01%
Vanguard Group Inc444,894$3.71M0.00%
Tekla Capital Management LLC200,000$1.67M0.05%
Wellington Management Group LLP139,566$1.16M0.00%
Monashee Investment Management LLC100,000$834.0K0.15%
Caas Capital Management LP75,000$626.0K0.05%
Norges Bank60,000$500.0K0.00%
DC Investments Management, LLC35,563$297.0K0.55%
Millennium Management LLC30,240$252.0K0.00%
Morgan Stanley28,236$235.0K0.00%
Two Sigma Investments, LP22,817$190.0K0.00%
Schonfeld Strategic Advisors LLC22,200$185.0K0.00%
Two Sigma Advisers, LP13,000$108.0K0.00%
Geode Capital Management, LLC12,786$106.0K0.00%
State Street Corp12,200$102.0K0.00%
Citadel Advisors LLC11,922$99.0K0.00%
Goldman Sachs Group Inc11,531$96.0K0.00%
Royal Bank of Canada1,000$8.00K0.00%
UBS Group AG946$8.00K0.00%
Wells Fargo & Company41$00.00%

Sold out (0)

Institutions that held TScan Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

None.